中国全科医学
中國全科醫學
중국전과의학
CHINESE GENERAL PRACTICE
2014年
32期
3885-3887
,共3页
小细胞肺癌%肿瘤标记,生物学%胃泌素释放肽前体%神经元特异性烯醇化酶
小細胞肺癌%腫瘤標記,生物學%胃泌素釋放肽前體%神經元特異性烯醇化酶
소세포폐암%종류표기,생물학%위비소석방태전체%신경원특이성희순화매
Small cell lung cancer%Tumor markers,biological%Pro - gastrin - releasing peptide%Neuron - specific enolase
目的:探讨胃泌素释放肽前体(ProGRP)在小细胞肺癌(SCLC)中的表达水平及临床意义。方法选择2011年5月-2013年5月安徽医科大学第一附属医院收治的初诊 SCLC 患者88例为 SCLC 组、非 SCLC 患者84例为 NSCLC 组、肺部良性病变患者50例为良性病变组,另选择同期在本院行体检健康者40例为对照组。采用 ELISA 法检测受试者血清ProGRP水平;采用放射免疫法检测血清神经元特异性烯醇化酶(NSE)水平。结果4组血清ProGRP和 NSE 水平比较,差异均有统计学意义(P <0.05),其中 SCLC 组和 NSCLC 组血清ProGRP和 NSE 水平均高于对照组和良性病变组(P <0.05);SCLC 组血清ProGRP和 NSE 水平均高于 NSCLC 组(P <0.05)。SCLC 广泛期血清ProGRP和NSE 水平均高于 SCLC 局限期(t =18.483、10.959,P <0.05)。治疗前 SCLC 缓解期、好转期和进展期ProGRP水平比较,差异无统计学意义(P >0.05);治疗后 SCLC 缓解期、好转期和进展期ProGRP水平比较,差异有统计学意义( P<0.05),其中进展期ProGRP水平均高于缓解期和好转期(P <0.05)。缓解期、好转期治疗后ProGRP水平均低于治疗前,进展期ProGRP水平治疗后高于治疗前(P <0.05)。结论血清ProGRP在 SCLC 中表达水平升高,尤其是进展期和广泛期;ProGRP在肿瘤的分期及预后判定有一定的临床价值。
目的:探討胃泌素釋放肽前體(ProGRP)在小細胞肺癌(SCLC)中的錶達水平及臨床意義。方法選擇2011年5月-2013年5月安徽醫科大學第一附屬醫院收治的初診 SCLC 患者88例為 SCLC 組、非 SCLC 患者84例為 NSCLC 組、肺部良性病變患者50例為良性病變組,另選擇同期在本院行體檢健康者40例為對照組。採用 ELISA 法檢測受試者血清ProGRP水平;採用放射免疫法檢測血清神經元特異性烯醇化酶(NSE)水平。結果4組血清ProGRP和 NSE 水平比較,差異均有統計學意義(P <0.05),其中 SCLC 組和 NSCLC 組血清ProGRP和 NSE 水平均高于對照組和良性病變組(P <0.05);SCLC 組血清ProGRP和 NSE 水平均高于 NSCLC 組(P <0.05)。SCLC 廣汎期血清ProGRP和NSE 水平均高于 SCLC 跼限期(t =18.483、10.959,P <0.05)。治療前 SCLC 緩解期、好轉期和進展期ProGRP水平比較,差異無統計學意義(P >0.05);治療後 SCLC 緩解期、好轉期和進展期ProGRP水平比較,差異有統計學意義( P<0.05),其中進展期ProGRP水平均高于緩解期和好轉期(P <0.05)。緩解期、好轉期治療後ProGRP水平均低于治療前,進展期ProGRP水平治療後高于治療前(P <0.05)。結論血清ProGRP在 SCLC 中錶達水平升高,尤其是進展期和廣汎期;ProGRP在腫瘤的分期及預後判定有一定的臨床價值。
목적:탐토위비소석방태전체(ProGRP)재소세포폐암(SCLC)중적표체수평급림상의의。방법선택2011년5월-2013년5월안휘의과대학제일부속의원수치적초진 SCLC 환자88례위 SCLC 조、비 SCLC 환자84례위 NSCLC 조、폐부량성병변환자50례위량성병변조,령선택동기재본원행체검건강자40례위대조조。채용 ELISA 법검측수시자혈청ProGRP수평;채용방사면역법검측혈청신경원특이성희순화매(NSE)수평。결과4조혈청ProGRP화 NSE 수평비교,차이균유통계학의의(P <0.05),기중 SCLC 조화 NSCLC 조혈청ProGRP화 NSE 수평균고우대조조화량성병변조(P <0.05);SCLC 조혈청ProGRP화 NSE 수평균고우 NSCLC 조(P <0.05)。SCLC 엄범기혈청ProGRP화NSE 수평균고우 SCLC 국한기(t =18.483、10.959,P <0.05)。치료전 SCLC 완해기、호전기화진전기ProGRP수평비교,차이무통계학의의(P >0.05);치료후 SCLC 완해기、호전기화진전기ProGRP수평비교,차이유통계학의의( P<0.05),기중진전기ProGRP수평균고우완해기화호전기(P <0.05)。완해기、호전기치료후ProGRP수평균저우치료전,진전기ProGRP수평치료후고우치료전(P <0.05)。결론혈청ProGRP재 SCLC 중표체수평승고,우기시진전기화엄범기;ProGRP재종류적분기급예후판정유일정적림상개치。
Objective To investigate the expression of pro - gastrin - releasing peptide(ProGRP)in small cell lung cancer(SCLC)and its significance. Methods Patients who were admitted to the First Affiliated Hospital of Anhui Medical U-niversity from May 2011 to May 2013 were selected as study subjects,88 newly diagnosed SCLC patients were included in SCLC group,84 patients without SCLC were included in NSCLC group,50 patients with benign lung disease were included in benign lesion group,and 40 healthy examinees in the same hospital during the same period were included in control group. Serum level of ProGRP was measured by ELISA,and serum level of neuron - specific enolase(NSE)was measured by radioimmunoassay. Results There were significant differences in serum levels of ProGRP and NSE among 4 groups(P < 0. 05). The serum levels of ProGRP and NSE in SCLC group and NSCLC group were significantly higher than those in control group and benign lesion group (P < 0. 05). The serum levels of ProGRP and NSE in SCLC group were significantly higher than those in NSCLC group(P <0. 05). The serum levels of ProGRP and NSE among SCLC patients in extended stage were significantly higher than those in limit-ed stage(t = 18. 483,10. 959,P < 0. 05). Before treatment,there was no significant difference in ProGRP level of SCLC pa-tients among remission stage,resolving stage and progressive stage( P > 0. 05). After treatment,there was significant differ-ence in ProGRP level of SCLC patients among remission stage,resolving stage and progressive stage(P < 0. 05),ProGRP level in progressive stage was significantly higher than that in remission stage and in resolving stage,respectively(P < 0. 05). In re-mission stage and resolving stage,ProGRP level after treatment was significantly lower than that before treatment(P < 0. 05). In progressive stage,ProGRP level after treatment was significantly lower than that before treatment(P < 0. 05). Conclusion Se-rum ProGRP level is high among SCLC patients,especially among SCLC patients in extended stage and in progressive stage. ProGRP provides clinical value to the tumor staging and prognosis judgement.